2. Protein Tyrosine Kinase/RTK
  3. VEGFR
  4. EYE1118

EYE1118 is an orally active, photoactivatable VEGFR2 inhibitor without acute hepatotoxicity. EYE1118 mediates light-enhanced inhibition via azide-functionalized receptor binding, and can utilize light-guided targeting to regulate its biodistribution in vivo. EYE1118 effectively inhibits angiogenesis, endothelial cell migration, VEGF-induced retinal leakage, and the size of choroidal neovascular lesions. EYE1118 has been applied in studies related to age-related macular degeneration, diabetic retinopathy, and choroidal neovascularization.

For research use only. We do not sell to patients.

EYE1118

EYE1118 Chemical Structure

CAS No. : 3037217-73-2

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

EYE1118 Related Antibodies

Top Publications Citing Use of Products

View All VEGFR Isoform Specific Products:

View All Isoforms
VEGFR1/Flt-1 VEGFR2/KDR/Flk-1 VEGFR3/Flt-4

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

EYE1118 is an orally active, photoactivatable VEGFR2 inhibitor without acute hepatotoxicity. EYE1118 mediates light-enhanced inhibition via azide-functionalized receptor binding, and can utilize light-guided targeting to regulate its biodistribution in vivo. EYE1118 effectively inhibits angiogenesis, endothelial cell migration, VEGF-induced retinal leakage, and the size of choroidal neovascular lesions. EYE1118 has been applied in studies related to age-related macular degeneration, diabetic retinopathy, and choroidal neovascularization[1].

IC50 & Target[1]

VEGFR2

 

In Vitro

EYE1118 potently inhibits VEGFR2 in a cell-free kinase assay, with 2.7-fold increased potency (IC50=9 nM) upon illumination compared to dark conditions (IC50=24 nM)[1].
EYE1118 (0.1-100 μM; 24 h) exhibits reduced cytotoxicity relative to vorolanib (HY-109019) in NIH/3T3 fibroblasts, with significantly lower toxicity at 10 μM and only marginal toxicity at 100 μM[1].
EYE1118 (1 h inhibitor incubation; 4 h VEGF stimulation) robustly inhibits VEGFR2 signaling in VEGFR2/NFAT reporter HEK293 cells, with significant light-dependent potentiation of activity under cold white and green LED (11.85-fold increase with green light, IC50 = 4.86 nM), but no effect under red LED light[1].
EYE1118 (0.1 nM-10 μM; 10 min pre-incubation; 12 h total incubation) potently inhibits HRMEC tubulogenesis, with 3.84-fold increased potency (IC50 = 134 nM) upon cold white LED exposure compared to dark conditions (IC50 = 515 nM), and is significantly more potent than vorolanib in both light and dark conditions[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

EYE1118 Related Antibodies

Cell Cytotoxicity Assay[1]

Cell Line: NIH/3T3 fibroblasts
Concentration: 0.1-100 μM
Incubation Time: 24 h
Result: Showed lower cytotoxicity against NIH/3T3 cells than its parental compound vorolanib, with this difference reaching statistical significance at 10 μM.
Exhibited only marginal toxicity at 100 μM relative to the vehicle control.

Western Blot Analysis[1]

Cell Line: VEGFR2/NFAT Reporter - HEK293
Concentration: 1-100 nM
Incubation Time: 1 h (inhibitor incubation); 10 min (VEGF stimulation)
Result: Did not substantially inhibit VEGF-induced phosphorylation of VEGFR2 at Y951 or Y1175 in the dark, even at 100 nM.
Significantly suppressed VEGF-induced phosphorylation of VEGFR2 at Y951 and Y1175 upon cold white LED exposure, with phosphorylation reduced to baseline levels at 100 nM and statistically significantly reduced relative to VEGF alone at 50 nM.
Left total VEGFR2 and β-actin levels unchanged, confirming effects were due to inhibited phosphorylation, not receptor degradation or reduced loading.
In Vivo

EYE1118 (1 mg/kg; i.g.; daily; 3 days) significantly inhibits VEGF-induced retinal vascular permeability in Long Evans rats[1].
EYE1118 (1 mg/kg; i.g.; daily; 3 days) starting 2 days before CNV induction significantly reduces CNV lesion area in C57BL/6JRj mice, with a very highly significant effect observed by day 5 post-induction[1].
EYE1118 (40 mg/kg; i.g.; single dose) does not induce acute hepatotoxicity in Balb/cJRj mice under standard or dim red light conditions[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Long Evans (male, 200-250 g, intravitreal injection of 50 ng/eye human VEGF-165)[1]
Dosage: 1 mg/kg
Administration: i.g.; daily; 3 days
Result: Significantly reduced VEGF-induced retinal vascular permeability, with permeability values not significantly different from control eyes and significantly lower than VEGF-only eyes (p=0.0019).
Animal Model: C57BL/6JRj (adult, 9 weeks old, laser-induced Bruch's membrane disruption)[1]
Dosage: 1 mg/kg
Administration: i.g.; daily; 3 days
Result: Reduced CNV lesion area very highly significantly relative to vehicle controls by day 5 post-induction (p<0.001).
Remained significantly reduced compared to vehicle controls on day 7 post-induction.
Animal Model: Balb/cJRj (male and female, 6-10 weeks old)[1]
Dosage: 40 mg/kg
Administration: i.g.; single dose
Result: Showed no evidence of liver architecture damage, necrosis, cellular stress, abnormal glycogen storage, or fibrosis via histopathological analysis, regardless of light condition.
Molecular Weight

496.95

Formula

C23H25ClN8O3
CAS No.
SMILES

CC1=C(C(N[C@H]2CCN(C(N(C)C)=O)C2)=O)C(C)=C(/C=C3C(NC4=CC(Cl)=C(N=[N+]=[N-])C=C4\3)=O)N1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

EYE1118 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

EYE11183037217-73-2EYE 1118EYE-1118VEGFRVascular endothelial growth factor receptorVEGFR2/NFAT reporter HEK293 cellsNIH/3T3 fibroblastsLong Evans ratsage-related macular degenerationdiabetic retinopathyC57BL/6JRj miceBalb/cJRj miceHRMECangiogenesisVEGFR2Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
EYE1118
Cat. No.:
HY-184142
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.